A recent study examined eye side effects from mirvetuximab soravtansine-gynx (Elahere), a drug approved by the U.S. Food and Drug Administration in 2024 for platinum-resistant ovarian cancer. Eye problems usually appeared early, about five weeks after starting treatment, and most were mild to moderate, including corneal damage and blurred vision.
However, researchers found an unexpected high rate of cataract progression. At peak severity, 37.5% of patients developed severe cataracts, and more than one-third required cataract surgery. This was surprising because doctors typically focus more on corneal issues than cataracts when monitoring patients on this drug.
Despite these findings, eye side effects were generally manageable. Many patients needed dose reductions or longer treatment intervals, but no one stopped therapy completely. With regular eye exams, artificial tears, and preventive steroid drops, most toxicities were reversible and controlled.